Compendium of Cancer Genome Aberrations

Volunteer Assignments and Opportunities: Difference between revisions

← Older editNewer edit →
VisualWikitext
No edit summary
Snehal.Patel (talk | contribs)
editor
270 edits
No edit summary
(45 intermediate revisions by 5 users not shown)
Line 1: Line 1:
Welcome!  For assignments, please see the "Author" column below.  If no name is present, volunteer to create content!


To volunteer, please contact the Associate Editor helping with your page of interest (email can be found on the <u>[[Leadership]]</u> page).
<br />
== WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content ==
{| class="wikitable"
{| class="wikitable"
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content
|-
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Disease'''!!'''Page Type'''!!'''Author'''
Line 22: Line 17:
|
|
|Fabiola Quintero-Rivera (FQR)
|Fabiola Quintero-Rivera (FQR)
|Date page was created
|
|
|
|-
|-
Line 32: Line 27:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 42: Line 37:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 66: Line 61:
|-
|-
|    Essential  Thrombocythaemia (ET)||Disease
|    Essential  Thrombocythaemia (ET)||Disease
|Rebecca Smith
|Rebecca Smith (trainee) + Fabiola Quintero-Rivera
|
|
|
|
|complete
|complete/pending faculty review
|
|
|FQR
|FQR
|
|
|8/1/21 FQR deleted "'''This page is under construction'''
|
|-
|-
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|Chelsea D. Kramish (trainee), Daynna J.Wolff
|(trainee), Daynna J.Wolff
|
|
|
|
|complete/pending faculty review
|pending faculty review
|
|
|FQR
|FQR
Line 87: Line 82:
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|Thomas Lee
|Thomas Lee
|
|8/17/2020
|
|9/7/2020
|complete
|complete
|
|
Line 95: Line 90:
|
|
|-
|-
|'''''Mastocytosis'''''||'''''Overview'''''||Shashi Shetty, Ph.D.
|'''''Mastocytosis'''''||'''''Overview'''''||'''Shashi Shetty, Ph.D.'''
|
|
|
|
Line 104: Line 99:
|-
|-
|    Cutaneous  Mastocytosis||Disease
|    Cutaneous  Mastocytosis||Disease
|Thuy Phung + Shuo-Shawn Liu (trainee)
|Thuy Phung/Shuo-Shawn Liu
|
|
|
|
|complete
|complete/pending adding content online as of 2/4/21
|
|
|FQR
|FQR
|
|
|8/1/21 FQR deleted "'''This page is under construction'''
|
|-
|-
|    Systemic Mastocytosis||Disease
|    Systemic Mastocytosis||Disease
Line 124: Line 119:
|-
|-
|    Mast Cell Sarcoma||Disease
|    Mast Cell Sarcoma||Disease
|Thuy Phung +Jordan Lowery (trainee)
|Thuy Phung +Jordan Lowery
|
|
|
|
Line 180: Line 175:
|Myeloid/Lymphoid Neoplasms with ETV6-JAK2
|Myeloid/Lymphoid Neoplasms with ETV6-JAK2
|Disease
|Disease
|Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
|Lauren R. Crowson (trainee)-Hindman + Daynna J. Wolff
|
|
|
|
Line 191: Line 186:
|Myeloid/Lymphoid Neoplasms with BCR-JAK2
|Myeloid/Lymphoid Neoplasms with BCR-JAK2
|Disease
|Disease
|Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
|Lauren R. Crowson (trainee) + Daynna J. Wolff
|
|
|
|
Line 230: Line 225:
|
|
|9/1/20
|9/1/20
|PENDING reference formatting
|PENDING
|
|
|FQR
|FQR
Line 242: Line 237:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 292: Line 287:
|    Myelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|    Myelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|
|
|
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 302: Line 297:
|
|
|9/1/20
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 329: Line 324:
|
|
|9/1/20
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 473: Line 468:
|
|
|-
|-
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg r
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg Conboy (Monash Health)
Conboy (Monash Health)
|
|
|
|
Line 482: Line 476:
|
|
|-
|-
|    Acute Myeloid Leukemia (AML) with  Mutated NPM1||Disease||Xinjie Xu
|    Acute Myeloid Leukemia (AML) with  Mutated NPM1||Disease||Xinjie Xu+Kay Weng Choy + Greg Conboy (Monash Health)
|
|
|
|
Line 763: Line 757:
|
|
|-
|-
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain (trainee) + Yassmine Akkari
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain + Yassmine Akkari
|
|
|
|
Line 835: Line 829:
|
|
|
|
|Complete
|PENDING
| ||YA
| ||YA
|
|
Line 954: Line 948:
|
|
|-
|-
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||Jamie Nagy
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||
|10/25/21
|
|
|
|
|PENDING
|
|
|SP
|SP
Line 963: Line 957:
|
|
|-
|-
|       Monoclonal B-cell  Lymphocytosis||Disease||Jamie Nagy
|       Monoclonal B-cell  Lymphocytosis||Disease||
|10/25/21
|
|
|
|
|PENDING
|
|
|SP
|SP
Line 1,129: Line 1,123:
|
|
|-
|-
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||Chen Yang, MD, PhD
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|           Primary  Amyloidosis||Disease||Heather E. Williams, PhD
|           Primary  Amyloidosis||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|           Light Chain  and Heavy Chain Deposition Disease||Disease||Chen Yang, MD, PhD
|           Light Chain  and Heavy Chain Deposition Disease||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||Sohini Anand
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
|8/31/2021
|
|9/15/2021
|
|PENDING
|
| ||SP
| ||SP
|
|
|
|
|-
|-
|         POEMS Syndrome||Disease||Sohini Anand, MBBS, and Tharanga Niroshini Senaratne, PhD
|         POEMS Syndrome||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|         TEMPI Syndrome||Disease||Sohini Anand, MBBS
|         TEMPI Syndrome||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid  Tissue (MALT Lymphoma)||Disease||Whayoung Lee (trainee)/Fabiola Quintero-Rivera
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid  Tissue (MALT Lymphoma)||Disease||Whayoung Lee, trainee)/Fabiola Quintero-Rivera
|3/9/21
|3/9/21
|
|
Line 1,273: Line 1,267:
|
|
|-
|-
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||Mahsa Khanlari, MD
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||
|
|
|
|
|
|?PENDING
|
|
|SP
|SP
Line 1,316: Line 1,310:
|
|
|-
|-
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||Laveniya Satgunaseelan
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||
|26/10/2021
|
|26/1/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
Line 1,388: Line 1,382:
|
|
|-
|-
|ALK-Positive Large B-cell Lymphoma||Disease||Nakasaki, Manando(trainee)+ Fabiola Quintero-Rivera
|ALK-Positive Large B-cell Lymphoma||Disease||
|6/1/21
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
Line 1,420: Line 1,414:
|
|
|-
|-
|   Multicentric Castleman  Disease||Disease||Sudha Arumugam
|   Multicentric Castleman  Disease||Disease||
|10/26/2021
|
|1/26/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Sudha Arumugam
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
|10/26/2021
|
|1/26/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|2021 template added
|-
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||Sudha Arumugam
|10/26/2021
|1/26/2022
|PENDING
| ||GC
|
|
|2021 template added
|-
|-
|Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||
|3/11/21
|
|06/28/2021
|
|Complete
|
|28/06/2021||GC
| ||GC
|28/06/2021
|
|
|
|-
|-
|Burkitt-Like Lymphoma with 11q Aberration||Disease||Lauren Shealy (trainee), Daynna Wolff
|Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
|10/13/21
|3/11/21
|
|
|PENDING
|PENDING
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|Burkitt-Like Lymphoma with 11q Aberration||Disease||
|
|
|
| ||GC
|
|
|-
|-
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
Line 1,468: Line 1,462:
|
|
|-
|-
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||Kate Berry, Greg Corboy
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||
|30/05/21
|
|30/08/21
|
|PENDING
|
| ||GC
| ||GC
|
|
|
|
|-
|-
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||Aiko Otsubo, Holli Drendel
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||
|7/30/21
|
|10/30/21
|
|Complete
|
|15/11/2021
| ||GC
|GC
|
|16/11/2021
|
|
|-
|-
Line 1,533: Line 1,526:
|
|
|-
|-
|Aggressive NK-cell Leukemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD
|Aggressive NK-cell Leukemia||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
Line 1,565: Line 1,558:
|
|
|-
|-
|    Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease||
|    Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease||
|
|
|
|
Line 1,581: Line 1,574:
|
|
|-
|-
|Adult T-cell Leukemia/Lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG
|Adult T-cell Leukemia/Lymphoma||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
Line 1,675: Line 1,668:
|
|
|-
|-
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||Peining Li, PhD
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|    Lymphomatoid  Papulosis||Disease||Peining Li, PhD
|    Lymphomatoid  Papulosis||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|    Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD
|    Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||Peining Li, PhD
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||Peining Li, PhD
|     Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||Peining Li, PhD
|     Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||Peining Li, PhD
|     Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||Peining Li, PhD
|     Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
Line 1,840: Line 1,833:
|
|
|-
|-
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease||Xiaolin (Lynn) Hu
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|    Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|    Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|    Mixed Cellularity Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|    Mixed Cellularity Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|    Lymphocyte-Depleted  Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|    Lymphocyte-Depleted  Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
Line 1,880: Line 1,873:
|
|
|-
|-
|Lymphomas Associated with HIV Infection||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|Lymphomas Associated with HIV Infection||Disease||
|11/2/21
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||
|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||
Line 1,963: Line 1,956:
|
|
|-
|-
|Histiocytic Sarcoma||Disease||Marie-France Gagnon, MD, Mayo Clinic (LGG fellow trainee), Xinjie Xu, PhD FACMG, Mayo Clinic
|Histiocytic Sarcoma||Disease||
|
|
|
| ||GC
|
|
|
|
|Complete
|10/01/2021
|GC
|10/01/2021
|Xinjie Xu
|-
|-
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
Line 1,980: Line 1,972:
|
|
|-
|-
|   Langerhans Cell  Histiocytosis||Disease||Prashant Deshpande
|   Langerhans Cell  Histiocytosis||Disease||
|10/26/2021
|
|1/26/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|   Langerhans Cell  Sarcoma||Disease||Prashant Deshpande
|   Langerhans Cell  Sarcoma||Disease||
|10/26/2021
|
|1/26/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|Indeterminate Dendritic Cell Tumour||Disease||
|Indeterminate Dendritic Cell Tumour||Disease||
Line 2,044: Line 2,036:
|
|
|-
|-
|Erdheim-Chester Disease||Disease||Prashant Deshpande
|Erdheim-Chester Disease||Disease||
|10/26/2021
|1/26/2022
|PENDING
| ||GC
|
|
|2021 template added
|-
| || ||
|
|
|
|
|
| ||GC
| ||
|
|
|
|
Line 2,211: Line 2,195:
|
|
|
|
|}<br />
== WHO Classification of Tumours of the Central Nervous System Content ==
{| class="wikitable"
|-
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
| || ||
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|'''''Medulloblastoma, WNT-activated'''''||'''''Disease'''''||Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|9/20/21
|
|
|PENDING
|
|
|
|
| ||
|
|
|2021 template added
|-
|}<br />
== WHO Classification of Soft Tissue and Bone Tumours Content ==
{| class="wikitable"
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|'''''Pending'''''||'''''Disease'''''||Pending
|Pending
|
|
|PENDING
|}
|
|
|
|
|-
|}<br />
 
== Gene-Specific Pages (IN PROCESS OF AUTOMATING - HOLD ON VOLUNTEERING) ==
{| class="wikitable sortable"
{| class="wikitable sortable"
|+Gene-Specific Pages
!'''Gene'''
!'''Gene'''
!'''Author'''
!'''Author'''
Retrieved from "https://content.ccga.io/index.php/Volunteer_Assignments_and_Opportunities"